{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T12:17:24Z","timestamp":1793535444683,"version":"4.5.0"},"reference-count":79,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:sec id=\"ab-prv250003-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The ongoing opioid-related overdose crisis in the US is increasingly affecting adolescents and is exacerbated by the widespread availability of illicitly manufactured fentanyl. Adolescents face significant gaps in care for prevention and treatment of opioid use and opioid-related harms. Regulatory changes have impacted the availability of 2 lifesaving medications, naloxone and buprenorphine. This narrative review summarizes the current knowledge of opioid use, overdoses, and opioid use disorder (OUD) among US adolescents in the context of fentanyl, and reviews the use of naloxone and buprenorphine, for overdose reversal and OUD treatment, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-prv250003-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Owing to their developmental stage, adolescents are uniquely vulnerable to initiating substances, experiencing substance-related harms, and developing substance use disorders. From 2018 through 2023, morbidity and mortality have increased from use of opioids, particularly fentanyl, among youth. Naloxone and buprenorphine are safe and highly effective medications for opioid overdose reversal and OUD treatment, respectively. Regulations for these medications have changed to address the worsening overdose epidemic. Naloxone is approved for over-the-counter sales (including by adolescents younger than 18 years). Any clinician with a US Drug Enforcement Administration\u2013controlled substance license can now prescribe buprenorphine for OUD without a waiver. These policy changes present critical opportunities to save lives and reduce inequities among adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-prv250003-3\">\n                    <jats:title>Conclusion and Relevance<\/jats:title>\n                    <jats:p>Harms from opioids are increasingly affecting adolescents with a notable rise in overdose fatalities in the past 5 years. Regulatory changes for naloxone and buprenorphine have occurred to improve access to both these medications. Despite these changes, adolescents continue to have low access to these life-saving interventions. Ensuring that clinicians have the knowledge to provide both medications to adolescents is a key step to addressing the epidemic of adolescent drug overdoses and reducing opioid-related harms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamapediatrics.2025.6113","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:30:26Z","timestamp":1770654626000},"page":"441","source":"Crossref","is-referenced-by-count":8,"title":["Naloxone and Buprenorphine Treatment for Adolescent Opioid Overdose and Opioid Use Disorder"],"prefix":"10.1001","volume":"180","author":[{"given":"Alexis","family":"Ball","sequence":"first","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Washington and Seattle Children\u2019s Research Institute, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Buresh","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, School of Medicine, University of Washington and Seattle Children\u2019s Hospital, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Hadland","sequence":"additional","affiliation":[{"name":"Division of Adolescent and Young Adult Medicine, Mass General for Children\/Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"14","key":"prv250003r3","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1001\/jama.2022.2847","article-title":"Trends in drug overdose deaths among US adolescents, January 2010 to June 2021.","volume":"327","author":"Friedman","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"prv250003r4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1056\/NEJMp2312084","article-title":"The overdose crisis among U.S. adolescents.","volume":"390","author":"Friedman","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"prv250003r5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1001\/jamapediatrics.2023.0793","article-title":"National trends in pediatric deaths from fentanyl, 1999-2021.","volume":"177","author":"Gaither","year":"2023","journal-title":"JAMA Pediatr"},{"issue":"1","key":"prv250003r6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities.","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"3","key":"prv250003r7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-1893","article-title":"Medication-assisted treatment of adolescents with opioid use disorders.","volume":"138","author":"Committee on Substance Use and Prevention","year":"2016","journal-title":"Pediatrics"},{"issue":"2S Suppl 1","key":"prv250003r9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update.","volume":"14","year":"2020","journal-title":"J Addict Med"},{"issue":"3","key":"prv250003r10","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jadohealth.2020.12.129","article-title":"Medication for adolescents and young adults with opioid use disorder.","volume":"68","author":"Society for Adolescent Health and Medicine","year":"2021","journal-title":"J Adolesc Health"},{"issue":"5","key":"prv250003r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.3209","article-title":"Naloxone prescriptions among commercially insured individuals at high risk of opioid overdose.","volume":"2","author":"Follman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"prv250003r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111136","article-title":"Analysis of rising cases of adolescent opioid use presentations to the emergency department and their management.","volume":"258","author":"Sidlak","year":"2024","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"prv250003r13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.annemergmed.2021.10.005","article-title":"Naloxone and buprenorphine prescribing following US emergency department visits for suspected opioid overdose: August 2019 to April 2021.","volume":"79","author":"Chua","year":"2022","journal-title":"Ann Emerg Med"},{"issue":"3","key":"prv250003r14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamapediatrics.2021.4606","article-title":"Access to medications for opioid use disorder and associated factors among adolescents and young adults: a systematic review.","volume":"176","author":"Pilarinos","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"6","key":"prv250003r15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jadohealth.2016.12.023","article-title":"Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder.","volume":"60","author":"Feder","year":"2017","journal-title":"J Adolesc Health"},{"issue":"12","key":"prv250003r16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226349","article-title":"Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17.","volume":"14","author":"Yang","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"prv250003r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2019.5183","article-title":"Receipt of addiction treatment after opioid overdose among medicaid-enrolled adolescents and young adults.","volume":"174","author":"Alinsky","year":"2020","journal-title":"JAMA Pediatr"},{"issue":"1","key":"prv250003r18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1377\/hlthaff.2023.00777","article-title":"Adolescent residential addiction treatment in the US: uneven access, waitlists, and high costs.","volume":"43","author":"King","year":"2024","journal-title":"Health Aff (Millwood)"},{"issue":"22","key":"prv250003r19","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1001\/jama.2023.6266","article-title":"Treatments used among adolescent residential addiction treatment facilities in the US, 2022.","volume":"329","author":"King","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"prv250003r21","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1001\/jamapediatrics.2024.3701","article-title":"Naloxone access laws and opioid-related overdose deaths in youths.","volume":"178","author":"Toce","year":"2024","journal-title":"JAMA Pediatr"},{"issue":"9","key":"prv250003r22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35416","article-title":"Clinician willingness to prescribe medications for opioid use disorder to adolescents in Indiana.","volume":"7","author":"Aalsma","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"prv250003r23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jama.2024.24121","article-title":"Trends in buprenorphine dispensing among adolescents and young adults in the US.","volume":"333","author":"Lee","year":"2025","journal-title":"JAMA"},{"key":"prv250003r24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.12.005","article-title":"Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.","volume":"106","author":"Comer","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"issue":"48","key":"prv250003r27","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.15585\/mmwr.mm7348a2","article-title":"Detection of illegally manufactured fentanyls and carfentanil in drug overdose deaths\u2014United States, 2021-2024.","volume":"73","author":"Tanz","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"prv250003r28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1280289","article-title":"\u201cTranq-dope\u201d overdose and mortality: lethality induced by fentanyl and xylazine.","volume":"14","author":"Smith","year":"2023","journal-title":"Front Pharmacol"},{"issue":"4","key":"prv250003r29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis.","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr Opin Psychiatry"},{"issue":"2","key":"prv250003r32","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-2752","article-title":"Youth and the opioid epidemic.","volume":"143","author":"Levy","year":"2019","journal-title":"Pediatrics"},{"key":"prv250003r33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/neuro.09.006.2010","article-title":"Adolescent development of the reward system.","volume":"4","author":"Galvan","year":"2010","journal-title":"Front Hum Neurosci"},{"issue":"June","key":"prv250003r34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.dcn.2016.10.004","article-title":"Sensitive periods of substance abuse: early risk for the transition to dependence.","volume":"25","author":"Jordan","year":"2017","journal-title":"Dev Cogn Neurosci"},{"issue":"6","key":"prv250003r35","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/add.15305","article-title":"Age-based preferences for risk communication in the fentanyl era: \u2018a lot of people keep seeing other people die and that\u2019s not enough for them\u2019.","volume":"116","author":"Gunn","year":"2021","journal-title":"Addiction"},{"issue":"50","key":"prv250003r36","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.15585\/mmwr.mm7150a2","article-title":"Drug overdose deaths among persons aged 10-19 years\u2014United States, July 2019-December 2021.","volume":"71","author":"Tanz","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"prv250003r38","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","article-title":"Opioid pharmacology.","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"issue":"5","key":"prv250003r39","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/00000542-197605000-00008","article-title":"Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action.","volume":"44","author":"Ngai","year":"1976","journal-title":"Anesthesiology"},{"issue":"5","key":"prv250003r40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13861","article-title":"Evaluation of strategies to enhance community-based naloxone distribution supported by an opioid settlement.","volume":"7","author":"Zang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"prv250003r41","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.103980","article-title":"Naloxone expansion is not associated with increases in adolescent heroin use and injection drug use: evidence from 44 US states.","volume":"114","author":"Bruzelius","year":"2023","journal-title":"Int J Drug Policy"},{"issue":"6","key":"prv250003r42","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/10903127.2017.1335818","article-title":"Incidence of naloxone redosing in the age of the new opioid epidemic.","volume":"21","author":"Klebacher","year":"2017","journal-title":"Prehosp Emerg Care"},{"issue":"1","key":"prv250003r43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/2042098617744161","article-title":"Naloxone dosage for opioid reversal: current evidence and clinical implications.","volume":"9","author":"Rzasa Lynn","year":"2018","journal-title":"Ther Adv Drug Saf"},{"issue":"5","key":"prv250003r44","doi-asserted-by":"publisher","first-page":"110","DOI":"10.15585\/mmwr.mm7305a4","article-title":"Comparison of administration of 8-milligram and 4-milligram intranasal naloxone by law enforcement during response to suspected opioid overdose\u2014New York, March 2022-August 2023.","volume":"73","author":"Payne","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"prv250003r46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13722-021-00249-3","article-title":"Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems.","volume":"16","author":"Bagley","year":"2021","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"prv250003r47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256752","article-title":"Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: a placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients.","volume":"17","author":"Moss","year":"2022","journal-title":"PLoS One"},{"key":"prv250003r48","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"4","key":"prv250003r49","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1097\/ADM.0000000000000922","article-title":"Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl.","volume":"16","author":"Varshneya","year":"2022","journal-title":"J Addict Med"},{"issue":"2","key":"prv250003r50","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1542\/9781581108910","article-title":"Medication-assisted treatment of opioid use disorder in adolescents and young adults.","volume":"25","author":"Cottrill","year":"2014","journal-title":"Adolesc Med State Art Rev"},{"key":"prv250003r52","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\u201cEverything is not right anymore\u201d: buprenorphine experiences in an era of illicit fentanyl.","volume":"74","author":"Silverstein","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"4","key":"prv250003r53","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/ADM.0000000000000952","article-title":"A plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era.","volume":"16","author":"Sue","year":"2022","journal-title":"J Addict Med"},{"issue":"2","key":"prv250003r54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/ADM.0000000000000635","article-title":"Executive summary of the focused update of the ASAM national practice guideline for the treatment of opioid use disorder.","volume":"14","author":"Crotty","year":"2020","journal-title":"J Addict Med"},{"issue":"5","key":"prv250003r55","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.addbeh.2010.01.001","article-title":"Unobserved versus observed office buprenorphine\/naloxone induction: a pilot randomized clinical trial.","volume":"35","author":"Gunderson","year":"2010","journal-title":"Addict Behav"},{"issue":"6","key":"prv250003r56","doi-asserted-by":"publisher","DOI":"10.1002\/emp2.12606","article-title":"Emergency department-initiated buprenorphine protocols: a national evaluation.","volume":"2","author":"Guo","year":"2021","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"prv250003r57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108778","article-title":"Cascade of care for office-based buprenorphine treatment in Bronx community clinics.","volume":"139","author":"Khalid","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"prv250003r58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1151\/spp021113","article-title":"The neurobiology of opioid dependence: implications for treatment.","volume":"1","author":"Kosten","year":"2002","journal-title":"Sci Pract Perspect"},{"key":"prv250003r59","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.drugalcdep.2015.09.001","article-title":"Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners.","volume":"156","author":"Vocci","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"prv250003r63","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/00952990802585380","article-title":"Brief vs. extended buprenorphine detoxification in a community treatment program: engagement and short-term outcomes.","volume":"35","author":"Katz","year":"2009","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"17","key":"prv250003r64","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2008.574","article-title":"Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.","volume":"300","author":"Woody","year":"2008","journal-title":"JAMA"},{"key":"prv250003r65","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1542\/peds.2020-023523G","article-title":"Principles of harm reduction for young people who use drugs.","volume":"147","author":"Kimmel","year":"2021","journal-title":"Pediatrics"},{"issue":"2","key":"prv250003r66","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/15332560802157065","article-title":"\u201cYou\u2019re nothing but a junkie\u201d: multiple experiences of stigma in an aging methadone maintenance population.","volume":"8","author":"Conner","year":"2008","journal-title":"J Soc Work Pract Addict"},{"key":"prv250003r67","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.749033","article-title":"Effectiveness of interventions for prevention of common infections among opioid users: A systematic review of systematic reviews.","volume":"10","author":"Puzhko","year":"2022","journal-title":"Front Public Health"},{"issue":"3","key":"prv250003r68","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jadohealth.2024.07.013","article-title":"A scoping review of evidence-based interventions and health-related services for youth who use nonmedical opioids in Canada and the United States.","volume":"76","author":"Marchand","year":"2025","journal-title":"J Adolesc Health"},{"key":"prv250003r69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108329","article-title":"Who stays in medication treatment for opioid use disorder? a national study of outpatient specialty treatment settings.","volume":"126","author":"Krawczyk","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"prv250003r70","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13011-020-00284-4","article-title":"Barriers, facilitators, and disparities in retention for adolescents in treatment for substance use disorders: a qualitative study with treatment providers.","volume":"15","author":"Acevedo","year":"2020","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"4","key":"prv250003r71","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1001\/jamapediatrics.2023.6493","article-title":"Treating adolescent opioid use disorder in primary care.","volume":"178","author":"Hadland","year":"2024","journal-title":"JAMA Pediatr"},{"issue":"1","key":"prv250003r72","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13722-024-00437-x","article-title":"Provider perceptions of systems-level barriers and facilitators to utilizing family-based treatment approaches in adolescent and young adult opioid use disorder treatment.","volume":"19","author":"Pielech","year":"2024","journal-title":"Addict Sci Clin Pract"},{"issue":"3","key":"prv250003r73","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.chc.2016.03.002","article-title":"Opioid use disorders.","volume":"25","author":"Sharma","year":"2016","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"1","key":"prv250003r74","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/08897077.2022.2060439","article-title":"Perceptions of peer and parental attitudes toward substance use and actual adolescent substance use: the impact of adolescent-confidant relationships.","volume":"43","author":"Marziali","year":"2022","journal-title":"Subst Abus"},{"issue":"6","key":"prv250003r75","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-053458","article-title":"State-by-state variability in adolescent privacy laws.","volume":"149","author":"Sharko","year":"2022","journal-title":"Pediatrics"},{"issue":"4","key":"prv250003r76","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.chc.2016.06.001","article-title":"Family-based treatments for adolescent substance use.","volume":"25","author":"Horigian","year":"2016","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"prv250003r77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108402","article-title":"Family involvement in treatment and recovery for substance use disorders among transition-age youth: research bedrocks and opportunities.","volume":"129","author":"Hogue","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"prv250003r78","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2025.4105","article-title":"Opioid use disorder and nonfatal opioid-involved overdose among medicaid-enrolled US youth, 2020-2023.","author":"Chen","year":"2025","journal-title":"JAMA Pediatr"},{"issue":"3","key":"prv250003r79","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.chc.2010.03.011","article-title":"Management of the adolescent with substance use disorders and comorbid psychopathology.","volume":"19","author":"Bukstein","year":"2010","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"prv250003r2","doi-asserted-by":"crossref","DOI":"10.15620\/cdc\/170565","volume-title":"Drug overdose deaths in the United States, 2003\u20132023. NCHS Data Brief, no 522","author":"Garnett","year":"2024"},{"key":"prv250003r20","volume-title":"Provisional drug overdose death counts","author":"Ahmad","year":"2025"},{"key":"prv250003r1","unstructured":"National Center for Drug Abuse Statistics. Drug overdose death statistics: fentanyl, opioids, heroin & more. Published 2019. Accessed January 11, 2026. https:\/\/drugabusestatistics.org\/drug-overdose-deaths\/"},{"key":"prv250003r8","unstructured":"AMA Task Force. Help save lives: co-prescribe naloxone to patients at risk of overdose. Published August 2017. Accessed March 20, 2023. https:\/\/www.aafp.org\/dam\/AAFP\/documents\/patient_care\/pain_management\/co-branded-naloxone.pdf"},{"key":"prv250003r25","unstructured":"US Centers for Disease Control and Prevention. Fentanyl facts. Published June 6, 2023. Accessed July 7, 2024. https:\/\/www.cdc.gov\/stop-overdose\/caring\/fentanyl-facts.html"},{"key":"prv250003r26","unstructured":"Health & Wellness Services. University of Colorado. 5 Things everyone should know about fentanyl. Published June 13, 2023. Accessed July 7, 2023. https:\/\/www.colorado.edu\/health\/blog\/fentanyl"},{"key":"prv250003r30","unstructured":"Panchal? N, Zitter? S. Teens, drugs, and overdose: contrasting pre-pandemic and current trends. KFF. Published October 15, 2024. Accessed January 5, 2026. https:\/\/www.kff.org\/mental-health\/issue-brief\/teens-drugs-and-overdose-contrasting-pre-pandemic-and-current-trends\/"},{"key":"prv250003r31","unstructured":"Substance Abuse and Mental Health Administration. 2023 NSDUH\u2014illicit drug use. Accessed August 30, 2024 https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt47100\/NSDUHDetailedTabs2023\/NSDUHDetailedTabs2023\/2023-nsduh-detailed-tables-sect5pe.htm"},{"key":"prv250003r37","unstructured":"US Centers for Disease Control and Prevention. What you should know about xylazine. Published July 17, 2023. Accessed January 5, 2026. https:\/\/www.cdc.gov\/overdose-prevention\/about\/what-you-should-know-about-xylazine.html"},{"key":"prv250003r45","unstructured":"American Society of Addiction Medicine. What is the definition of addiction? Published 2023. Accessed July 28, 2023. https:\/\/www.asam.org\/quality-care\/definition-of-addiction"},{"key":"prv250003r51","unstructured":"SAMHSA. Buprenorphine quick start guide. Accessed August 20, 2024. http:\/\/www.samhsa.gov\/sites\/default\/files\/quick-start-guide.pdf"},{"key":"prv250003r60","unstructured":"The ASAM national practice guideline for the treatment of opioid use disorder\u20142020 focused update. Accessed 4 February, 2023. https:\/\/www.asam.org\/quality-care\/clinical-guidelines\/national-practice-guideline"},{"key":"prv250003r61","unstructured":"ASAM criteria. Default. https:\/\/www.asam.org\/asam-criteria"},{"key":"prv250003r62","unstructured":"Providers Clinical Support System. Home. Published August 26, 2022. Accessed August 20, 2023. https:\/\/pcssnow.org\/"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2844826\/jamapediatrics_ball_2026_rv_250003_1775143789.02489.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:01:05Z","timestamp":1775487665000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2844826"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2025.6113","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}